Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
MOMA Therapeutics
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Amgen
National Institutes of Health Clinical Center (CC)
Rutgers, The State University of New Jersey
Arcus Biosciences, Inc.
City of Hope Medical Center
National Cancer Institute (NCI)
Atavistik Bio, Inc
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
Duke University
AstraZeneca
Poseida Therapeutics, Inc.
AstraZeneca
University of Washington
Memorial Sloan Kettering Cancer Center
Novartis
M.D. Anderson Cancer Center
NeoTX Therapeutics Ltd.
M.D. Anderson Cancer Center
BicycleTx Limited
BicycleTx Limited
SystImmune Inc.
Masonic Cancer Center, University of Minnesota
TCR2 Therapeutics
Exelixis
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Cancer Research UK
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
University of Chicago
OncoC4, Inc.
Tempus AI
Carisma Therapeutics Inc
UNICANCER
University of Toronto
Sunnybrook Health Sciences Centre
Shanghai PerHum Therapeutics Co., Ltd.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc